tiprankstipranks
Top Stocks
Top Analyst StocksTop Smart Score StocksTop Insiders Stocks
Popular
Stock ScreenerTop Online Growth StocksTrending StocksPenny Stock Screener
Dividend Investing
Dividend CalculatorDividend Yield CalculatorDividend StocksDividend NewsDividend Calendar
ETFs
ETF CenterSPY ETFQQQ ETF
Stock Comparison
ChatGPT StocksValue StocksAirline StocksAI StocksOil StocksBank StocksFAANG StocksCompare More Stocks…
Calendars
IPO CalendarEarnings Calendar
Popular
Dividend CalendarEconomic Calendar
New
Market HolidaysDaily Analyst RatingsDaily Insider Trading
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Stock Market NewsStock Analysis & Ideas
Popular
ETF NewsGlobal Markets NewsExpert SpotlightTipRanks LabsEarnings Reports InsightsMarket BreakdownsDividend Stock NewsCrypto News
My PortfolioMy PerformanceMy Portfolio AnalysisCrowd InsightsMy Watchlist
About Us
About TipRanksContact Us
Working with TipRanks
Enterprise SolutionsBest Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert Center
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
ETF Center
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Smart Score Stocks
Analysts' Hot Stocks
Insiders' Hot Stocks
Popular
Trending Stocks
Fastest Growing Websites
Hot
Penny Stocks
Market Movers
My Experts
Top Firms
Top Wall Street Analysts
Top Financial Bloggers
Top Corporate Insiders
Popular
Top Hedge Fund Managers
Top Individual Investors
Stock Screener
Stock Comparison
Dividend Calculator
Popular
ETF Center
Dividend Yield Calculator
Daily Stock Ratings
Daily Insider Transactions
Stock ComparisonPOPULAR COMPARISONS
Dividend Stocks
ChatGPT Stocks
Airline Stocks
AI Stocks
My Portfolio
My Performance
My Portfolio Analysis
Crowd Insights
Earnings Calendar
Popular
Dividend Calendar
Economic Calendar
New
IPO Calendar
Stock Market Holidays
Market News
ETF News
Stock Analysis & Ideas
Popular
Global Markets News
Expert Spotlight
Tipranks Labs
Earnings Reports Insights
Market Breakdowns
Dividend Stock News
Crypto News
About TipRanks
For Business
Become an Affiliate
Reviews
Contact Us
Plans & Pricing

MEIP Stock Latest News

Infinity Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
The FlyInfinity Pharmaceuticals downgraded to Neutral from Overweight at Piper Sandler
27d ago
INFI
MEIP
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.
Press ReleasesALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Infinity Pharmaceuticals, Inc.
28d ago
INFI
MEIP
MEI, Infinity report all-stock transaction to advance three oncology candidates
The FlyMEI, Infinity report all-stock transaction to advance three oncology candidates
28d ago
INFI
MEIP
MEI Pharma price target lowered to $2 from $5 at H.C. Wainwright
The FlyMEI Pharma price target lowered to $2 from $5 at H.C. Wainwright
1M ago
MEIP
MEI Pharma reports Q2 EPS 8c, consensus (14c)
The FlyMEI Pharma reports Q2 EPS 8c, consensus (14c)
1M ago
MEIP
MEI Pharma downgraded to Underperform from Hold at Jefferies
The FlyMEI Pharma downgraded to Underperform from Hold at Jefferies
1M ago
MEIP
MEI Pharma cut to Hold at Truist after decision to discontinue zandelisib
The FlyMEI Pharma cut to Hold at Truist after decision to discontinue zandelisib
4M ago
MEIP
MEI Pharma downgraded to Neutral from Buy at BTIG
The FlyMEI Pharma downgraded to Neutral from Buy at BTIG
4M ago
MEIP
MEI Pharma downgraded to Hold from Buy at Truist
The FlyMEI Pharma downgraded to Hold from Buy at Truist
4M ago
MEIP
MEI Pharma announces 30% workforce reduction
The FlyMEI Pharma announces 30% workforce reduction
4M ago
MEIP
MEI Pharma announces realignment of clinical development efforts
The FlyMEI Pharma announces realignment of clinical development efforts
4M ago
MEIP
MEI Pharma, Kyowa Kirin to discontinue zandelisib development outside Japan
The FlyMEI Pharma, Kyowa Kirin to discontinue zandelisib development outside Japan
4M ago
MEIP
MEI Pharma reports Q1 EPS (12c), consensus (14c)
The FlyMEI Pharma reports Q1 EPS (12c), consensus (14c)
4M ago
MEIP
MEI Pharma: There’s More Upside Ahead, Says Analyst Who Made a Winning Call
Stock Analysis & IdeasMEI Pharma: There’s More Upside Ahead, Says Analyst Who Made a Winning Call
1y ago
MEIP
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10
Stock Analysis & Ideas2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10
1y ago
CBAY
MEIP
MEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib
Market NewsMEI Pharma Presents Positive Preclinical Data For Cancer Drug Voruciclib
2y ago
MEIP
MEI Pharma (MEIP) Stock Takes a Hit but This Analyst Keeps the Faith
Stock Analysis & IdeasMEI Pharma (MEIP) Stock Takes a Hit but This Analyst Keeps the Faith
3y ago
MEIP
Billionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks
Stock Analysis & IdeasBillionaire Ken Griffin Pulls the Trigger on These 3 Penny Stocks
3y ago
KZR
MEIP
tipranks
TipRanks is a comprehensive research tool that helps investors make better, data-driven investment decisions.
Find Us on
twitterstocktwitsfacebooklinkedininstagram
Newsletter SubscriptionEnter your email to receive our newsletter
iosandroid
SitemapTerms of UsePrivacy PolicyFAQ
Research ToolsTop Smart Score StocksTrending StocksDaily Stock RatingsStock ScreenerStock ComparisonAnalysts' Top StocksDaily Insider TransactionsInsiders' Hot StocksExpert Center
CalendarsEarnings CalendarDividend CalendarIPO CalendarStock Market Holidays
EducationGlossaryTipRanks Labs
PlansPlans & PricingAPI for Institutions
CompanyAbout TipRanksContact UsReviews
Disclaimer: The TipRanks Smart Score performance is based on backtested results. Backtested performance is not an indicator of future actual results. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. Backtested results are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. General assumptions include: XYZ firm would have been able to purchase the securities recommended by the model and the markets were sufficiently liquid to permit all trading. Changes in these assumptions may have a material impact on the backtested returns presented. Certain assumptions have been made for modeling purposes and are unlikely to be realized. No representations and warranties are made as to the reasonableness of the assumptions. This information is provided for illustrative purposes only. Backtested performance is developed with the benefit of hindsight and has inherent limitations. Specifically, backtested results do not reflect actual trading or the effect of material economic and market factors on the decision-making process. Since trades have not actually been executed, results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity, and may not reflect the impact that certain economic or market factors may have had on the decision-making process. Further, backtesting allows the security selection methodology to be adjusted until past returns are maximized. Actual performance may differ significantly from backtested performance. Backtested results are adjusted to reflect the reinvestment of dividends and other income and, except where otherwise indicated, are presented gross-of fees and do not include the effect of backtested transaction costs, management fees, performance fees or expenses, if applicable. Please note all regulatory considerations regarding the presentation of fees must be taken into account. No cash balance or cash flow is included in the calculation.